Drug intelligence / Profile preview

cefepime + avibactam

Development stage
Phase 3
Lead developer
Pfizer
Modality
Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
Administration
Intravenous
01

Overview

Cefepime + avibactam is a combination antibiotic therapy under investigation for the treatment of infections caused by multidrug-resistant Gram-negative bacteria. Cefepime is a fourth-generation cephalosporin antibiotic that exerts its bactericidal effect by binding to penicillin-binding proteins (PBPs), thereby inhibiting bacterial cell wall synthesis and leading to cell lysis and death. Avibactam is a non-beta-lactam beta-lactamase inhibitor that protects cefepime from degradation by inhibiting certain beta-lactamases, including class A, C, and some D enzymes. This combination aims to extend the spectrum of activity of cefepime against resistant organisms, particularly those producing extended-spectrum beta-lactamases (ESBLs) or carbapenemases.

Other names
YK 1169YK1169YK-1169
02

Targets

Class A BL (Class A beta-lactamase)PBP (Penicillin-binding protein family)

Beyond the preview

Go deeper on cefepime + avibactam.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cefepime + avibactam.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call